bun107 Antibody

What is bun107 and why is it significant in research applications?

bun107 is a WD repeat-containing protein encoded by the bun107 gene in Schizosaccharomyces pombe (fission yeast). The protein is classified as a protein-coding gene with Entrez Gene ID 2543160. Its significance in research stems from its WD repeat domains, which typically serve as platforms for protein-protein interactions in various cellular processes. WD repeat proteins often function in signal transduction, transcriptional regulation, and cell cycle control, making antibodies against bun107 valuable tools for investigating these fundamental cellular mechanisms in S. pombe models. Understanding bun107's function contributes to our broader knowledge of conserved cellular processes across eukaryotes.

What are the molecular characteristics of the bun107 protein that influence antibody development?

The bun107 protein (NP_592926.1) contains WD repeat domains, which consist of approximately 40-60 amino acid motifs often terminating in tryptophan-aspartic acid (WD) dipeptides. These domains form a β-propeller structure with multiple blades that create a stable platform for protein interactions. When developing antibodies against bun107, researchers must consider several key factors: (1) the three-dimensional structure of the WD repeats, which may hide potential epitopes; (2) the high conservation of WD domains across species, which can affect antibody specificity; and (3) the need to target unique regions outside the conserved WD motifs to ensure specificity for bun107 rather than other WD repeat proteins. These characteristics dictate epitope selection strategies and validation approaches specific to bun107 antibodies.

How does one distinguish between specific and non-specific binding when using bun107 antibodies?

Distinguishing specific from non-specific binding is critical when working with bun107 antibodies. A robust approach employs multiple validation strategies:

First, examine subcellular localization patterns—bun107 should demonstrate specific cellular distribution consistent with its biological function as a WD repeat protein. Second, perform antibody titration experiments to identify the optimal concentration where specific signal is maximized while background is minimized. Third, implement orthogonal validation methods such as Western blotting or mass spectrometry to confirm target specificity. Fourth, use genetic controls such as knockouts or knockdowns of bun107 to confirm signal absence in negative controls.

For conclusive validation, employ independent epitope validation by testing multiple antibodies targeting different regions of bun107. When signals from these antibodies correlate strongly, this provides robust evidence of specificity. Careful examination of staining patterns across multiple experimental conditions helps distinguish true signal from artifacts.

What are the optimal fixation and retrieval conditions for immunohistochemistry with bun107 antibodies?

For optimal immunohistochemistry (IHC) results with bun107 antibodies, fixation and antigen retrieval conditions must be carefully optimized. Formalin fixation (10% neutral buffered formalin for 24-48 hours) is generally recommended as it preserves cellular architecture while maintaining protein antigenicity. After fixation and paraffin embedding, sections typically require antigen retrieval to unmask epitopes.

For bun107, which contains WD repeat domains, heat-induced epitope retrieval (HIER) often yields superior results compared to proteolytic methods. Test both citrate buffer (pH 6.0) and Tris-EDTA buffer (pH 9.0) to determine which provides optimal signal-to-noise ratio. In many cases, high-pH Tris-EDTA buffer more effectively retrieves epitopes from WD repeat proteins.

The protocol should include:

• Deparaffinization and rehydration of tissue sections

• Antigen retrieval (typically 20 minutes at 95-98°C in the selected buffer)

• Cooling gradually to room temperature (20 minutes)

• Blocking of endogenous peroxidase activity and non-specific binding sites

• Incubation with optimized antibody dilution (determined through titration)

Post-validation, document all conditions meticulously to ensure reproducibility across experiments.

How can I optimize Western blot protocols specifically for bun107 detection?

Optimizing Western blot protocols for bun107 detection requires attention to several key parameters. As a WD repeat-containing protein from S. pombe, bun107 requires specific conditions for reliable detection:

Sample preparation should include protease inhibitors to prevent degradation, and lysis buffers should be compatible with WD repeat protein extraction (RIPA or NP-40 based buffers often work well). For gel electrophoresis, 10-12% polyacrylamide gels typically provide good resolution for bun107.

The transfer step is critical—use PVDF membranes for better protein retention and signal detection. For blocking, 5% non-fat dry milk in TBST is usually effective, but for phospho-specific detection, BSA-based blocking may be preferable.

Antibody dilution requires careful titration—start with manufacturer recommendations and adjust based on signal-to-noise ratio. For bun107 detection, overnight incubation at 4°C often yields cleaner results than shorter incubations at room temperature. To optimize wash steps, use TBST with 0.1% Tween-20 and perform at least three 10-minute washes.

Always include positive and negative controls to validate results. For bun107, S. pombe extract serves as a positive control, while extracts from strains with bun107 deletion can serve as negative controls.

What cross-reactivity concerns should researchers address when using bun107 antibodies across different yeast species?

Cross-reactivity is a significant concern when using bun107 antibodies across different yeast species due to the conserved nature of WD repeat domains. Researchers should address several key considerations:

First, perform sequence homology analysis to identify potential cross-reactive proteins. WD repeat domains share structural similarity across species, but sequence variations exist. Compare bun107 from S. pombe with homologs in target species using alignment tools to identify regions of high conservation that may lead to cross-reactivity.

Third, consider epitope-mapping to determine which region of bun107 the antibody recognizes. Antibodies targeting highly conserved regions of WD repeats will likely show broader cross-reactivity than those targeting unique regions specific to S. pombe bun107.

Fourth, implement genetic controls when possible, such as testing the antibody against knockout strains for each species to confirm specificity.

What are the essential validation steps for confirming bun107 antibody specificity in research applications?

Essential validation steps for confirming bun107 antibody specificity follow a systematic approach aligned with established validation pillars:

• Localization validation: First, confirm that the antibody produces staining patterns consistent with the expected biological distribution of bun107 as a WD repeat protein. This includes examining both tissue type and subcellular localization patterns, which should align with known or predicted functions of WD repeat proteins.

• Antibody optimization: Perform quantitative titration experiments to determine the optimal antibody concentration that maximizes specific signal while minimizing background. This step is crucial for all subsequent validation procedures and should include optimization of antigen retrieval methods and incubation conditions.

• Orthogonal validation: Implement independent methodologies to confirm target specificity. For bun107, this typically involves Western blotting to confirm the presence of a band at the expected molecular weight, mass spectrometry of immunoprecipitated material, or RNA expression correlation studies.

• Genetic validation: Utilize genetic approaches, including testing the antibody against samples with altered bun107 expression. This could involve S. pombe strains with bun107 gene deletion, knockdown, or overexpression to demonstrate corresponding changes in antibody signal.

• Independent epitope validation: Test multiple antibodies targeting different epitopes of bun107. Strong correlation between signals from these distinct antibodies provides compelling evidence for specificity.

• Reproducibility assessment: Confirm that the antibody produces consistent results across multiple experiments, different sample preparations, and various lots of the antibody.

This comprehensive approach ensures that research findings based on bun107 antibody applications are reliable and reproducible.

How can I implement the "five pillars of antibody validation" specifically for bun107 antibody research?

Implementing the five pillars of antibody validation for bun107 research requires adapting general principles to this specific WD repeat protein:

Pillar 1: Genetic strategies
For bun107, utilize S. pombe strains with gene deletion or RNAi-mediated knockdown. Compare antibody signals between wild-type and genetically modified samples—true bun107 antibodies should show significantly reduced or absent signal in knockout models. For added rigor, implement inducible expression systems to demonstrate corresponding signal increases with controlled bun107 expression.

Pillar 2: Orthogonal strategies
Correlate antibody detection with independent measurements of bun107 expression. Compare immunohistochemistry results with RNA-seq or qPCR data measuring bun107 mRNA levels. Additionally, use mass spectrometry to identify proteins captured by immunoprecipitation with the bun107 antibody, confirming the presence of the target protein and identifying potential cross-reactants.

Pillar 3: Independent antibody strategies
Validate using multiple antibodies targeting non-overlapping epitopes of bun107. Strong correlation between signals from these distinct antibodies provides compelling evidence for specificity. Map the epitopes recognized by each antibody to ensure they target different regions of the protein.

Pillar 4: Expression patterns
Examine whether the observed staining pattern matches known or predicted subcellular localization of bun107. As a WD repeat protein, bun107 may associate with specific cellular structures or compartments based on its protein interaction functions.

Pillar 5: Independent expression systems
Test the antibody against recombinant bun107 expressed in heterologous systems (e.g., E. coli, mammalian cells) at controlled concentrations. This approach helps establish detection limits and confirms antibody recognition of the protein in different contexts.

Document all validation results systematically, including positive and negative controls, to establish the reliability of the bun107 antibody for specific research applications.

What quantitative methods can accurately assess bun107 antibody sensitivity and specificity?

Several quantitative methods can rigorously assess bun107 antibody sensitivity and specificity:

Titration curve analysis: Generate quantitative titration curves by testing serial dilutions of the antibody against fixed amounts of target protein. Plot signal intensity versus antibody concentration and determine the EC50 (half-maximal effective concentration). This approach identifies the optimal working concentration and establishes the dynamic range of detection.

Signal-to-noise ratio (SNR) measurement: Calculate the ratio between specific signal (from positive controls) and background signal (from negative controls). For bun107 antibodies, an SNR > 3 generally indicates acceptable specificity, while values > 10 suggest excellent specificity. Implement this measurement across multiple experimental conditions to ensure robust performance.

Competitive binding assays: Assess specificity by pre-incubating the antibody with purified bun107 protein before application to samples. Genuine bun107 antibodies will show dose-dependent signal reduction with increasing concentrations of competitive antigen.

Quantitative immunoprecipitation: Measure the percentage of target protein captured from lysates under standardized conditions. For specific bun107 antibodies, immunoprecipitation efficiency should typically exceed 70% when using optimal antibody concentrations.

These methods provide quantitative metrics for antibody performance, facilitating objective comparison between different antibodies or experimental conditions in bun107 research.

How can I address weak or inconsistent signals when using bun107 antibodies in immunofluorescence studies?

When encountering weak or inconsistent signals with bun107 antibodies in immunofluorescence applications, implement this systematic troubleshooting approach:

Fixation optimization: Test multiple fixation methods, as WD repeat proteins like bun107 may be sensitive to specific fixatives. Compare paraformaldehyde (2-4%), methanol, and acetone fixation to determine which best preserves epitope accessibility while maintaining cellular architecture.

Antigen retrieval enhancement: For fixed tissues or cells, optimize antigen retrieval by testing various buffers (citrate pH 6.0 vs. Tris-EDTA pH 9.0) and retrieval times. WD repeat proteins may require more aggressive retrieval conditions to expose epitopes within their complex β-propeller structures.

Detergent permeabilization adjustment: Optimize membrane permeabilization by testing different detergents (Triton X-100, Tween-20, saponin) at various concentrations. The complex structure of bun107 may require specific permeabilization conditions for antibody accessibility.

Signal amplification implementation: For inherently low-abundance targets like some WD repeat proteins, employ signal amplification systems such as tyramide signal amplification (TSA), which can increase sensitivity 10-100 fold while maintaining specificity.

Blocking optimization: Test alternative blocking reagents (BSA, normal serum, commercial blocking solutions) to reduce background while preserving specific signal. Some blocking agents may mask bun107 epitopes.

Incubation conditions refinement: Extend primary antibody incubation times (overnight at 4°C) or adjust temperatures to enhance binding kinetics. Similarly, optimize secondary antibody conditions for maximum signal development.

Antibody concentration reassessment: Perform detailed titration experiments to identify the optimal concentration where specific signal is maximized while background is minimized.

Document all optimization steps systematically to establish reproducible protocols for bun107 detection in immunofluorescence applications.

What control samples are essential when validating new lots of bun107 antibodies?

When validating new lots of bun107 antibodies, incorporating the following essential control samples ensures reliable performance assessment:

Positive biological controls: Include S. pombe wild-type samples known to express bun107 at detectable levels. These samples establish the expected signal pattern and intensity baseline for comparison.

Negative biological controls: Utilize S. pombe strains with bun107 gene deletion or knockdown. These samples confirm antibody specificity by demonstrating absence or significant reduction of signal.

Overexpression controls: Samples with artificially elevated bun107 expression verify the antibody's ability to detect increased target levels and help establish the dynamic range of detection.

Cross-reactivity controls: Include samples containing proteins with similar domains (other WD repeat proteins) to assess potential cross-reactivity, particularly important for bun107 due to the conserved nature of WD repeat domains.

Previous lot comparison samples: Maintain reference samples tested with previously validated antibody lots to enable direct comparison of staining patterns and intensities.

Epitope competition controls: Pre-incubate the antibody with purified recombinant bun107 protein or specific peptide fragments containing the epitope before application to samples. This should abolish specific staining if the antibody is truly specific.

Tissue panel for localization assessment: For antibodies intended for immunohistochemistry, include a panel of tissues with known expression patterns of bun107 to confirm expected localization patterns.

Document all control results systematically in a validation report that includes images, quantitative measurements, and detailed experimental conditions to facilitate lot-to-lot comparison and ensure continued reliability in research applications.

How do post-translational modifications of bun107 affect antibody recognition and experimental outcomes?

Post-translational modifications (PTMs) of bun107 can significantly affect antibody recognition and experimental outcomes in several important ways:

Phosphorylation effects: WD repeat proteins like bun107 often undergo phosphorylation, which can alter protein conformation and epitope accessibility. Phosphorylation may either expose or mask antibody binding sites, leading to variable detection efficiency depending on the cellular context and signaling state. Researchers should determine whether their bun107 antibody is sensitive to phosphorylation states by comparing detection in samples treated with or without phosphatase inhibitors.

Ubiquitination considerations: Ubiquitination of bun107 may occur as part of protein turnover regulation. This large modification can sterically hinder antibody access to nearby epitopes or create conformational changes affecting distant epitopes. When studying bun107 degradation pathways, researchers should verify whether their antibody can detect both ubiquitinated and non-ubiquitinated forms.

Glycosylation implications: Though less common in intracellular proteins, potential glycosylation of bun107 could affect antibody binding. If glycosylation is suspected, compare antibody detection in samples treated with deglycosylation enzymes versus untreated controls.

Conformational dependence: Some antibodies recognize conformational epitopes that span multiple regions of the folded protein. PTMs can alter protein folding, potentially disrupting these epitopes. Testing antibody performance under native versus denaturing conditions helps identify conformation-sensitive antibodies.

PTM-specific antibodies: For advanced studies of bun107 regulation, consider developing or obtaining PTM-specific antibodies that selectively recognize modified forms of the protein (e.g., phospho-bun107). These require rigorous validation comparing detection in wild-type versus samples where the modification site is mutated.

Researchers should systematically characterize how relevant PTMs affect their specific bun107 antibody and document these effects to interpret experimental results accurately.

How can bun107 antibodies be effectively employed in chromatin immunoprecipitation (ChIP) experiments?

Effectively employing bun107 antibodies in chromatin immunoprecipitation (ChIP) experiments requires specialized optimization due to the nature of WD repeat proteins and their potential roles in chromatin-associated complexes:

Cross-linking optimization: For bun107 ChIP, test various formaldehyde concentrations (0.75-2%) and cross-linking times (10-20 minutes) to determine optimal conditions that preserve protein-DNA interactions without over-fixing, which can mask epitopes. Dual cross-linking with both formaldehyde and protein-specific cross-linkers (like DSG or EGS) may better capture indirect DNA associations of WD repeat proteins.

Sonication parameters: Optimize sonication conditions to generate DNA fragments of 200-500bp while preserving bun107 epitope integrity. Test multiple sonication protocols (varying amplitude and cycle numbers) and verify fragment size distribution by agarose gel electrophoresis.

Antibody validation for ChIP: Validate bun107 antibodies specifically for ChIP applications using ChIP-grade positive controls and IgG negative controls. Calculate enrichment by qPCR comparing to input samples and IgG controls, with enrichment >5-fold generally indicating successful immunoprecipitation.

Epitope accessibility enhancement: For challenging targets like WD repeat proteins, incorporate epitope accessibility-enhancing steps such as: (1) extended sonication for better chromatin opening; (2) using higher SDS concentrations in lysis buffers (with appropriate dilution before immunoprecipitation); and (3) testing multiple antibodies targeting different epitopes of bun107.

Sequential ChIP approach: To study bun107 co-occupancy with other factors, implement sequential ChIP (re-ChIP) protocols where chromatin is immunoprecipitated first with bun107 antibody, then eluted under mild conditions and re-immunoprecipitated with antibodies against suspected interacting partners.

Data analysis considerations: For ChIP-seq applications, utilize appropriate controls and peak-calling algorithms suited for factors without direct DNA binding, as WD repeat proteins typically associate with chromatin indirectly through protein complexes.

This comprehensive approach enables reliable investigation of bun107's potential roles in chromatin regulation and transcriptional control processes.

How can artificial intelligence tools improve bun107 antibody design and validation processes?

Artificial intelligence tools are revolutionizing bun107 antibody design and validation through several innovative approaches:

Epitope prediction and optimization: Deep learning algorithms now predict optimal epitopes for bun107 antibody generation by analyzing protein sequence, structure, and surface accessibility. These tools can identify unique regions within WD repeat domains that maximize specificity while avoiding cross-reactivity with similar proteins. For bun107, AI tools can distinguish between conserved structural elements of WD repeats and regions unique to this specific protein.

Structure-guided antibody design: RFdiffusion and similar AI platforms can generate novel antibody structures optimized for binding specific epitopes on bun107. These computational approaches design complementarity-determining regions (CDRs) with ideal shape and chemical complementarity to target epitopes, significantly improving binding affinity and specificity compared to traditional methods.

Validation image analysis: Convolutional neural networks (CNNs) and other deep learning architectures now automate and standardize the analysis of immunohistochemistry and immunofluorescence images during bun107 antibody validation. These systems objectively quantify staining patterns, intensity distributions, and colocalization metrics, reducing human bias and increasing reproducibility in validation processes.

Cross-reactivity prediction: AI models trained on protein sequence and structural data can predict potential cross-reactive targets for candidate bun107 antibodies before experimental testing. This computational prescreening identifies antibodies likely to exhibit high specificity, directing resources toward the most promising candidates.

Validation protocol optimization: Machine learning algorithms analyze historical validation data to recommend optimal protocols for specific antibody-antigen pairs. For bun107 validation, these systems can suggest ideal fixation methods, antigen retrieval conditions, and incubation parameters based on the antibody's characteristics and the target epitope.

The implementation of AI tools in bun107 antibody research has dramatically accelerated development timelines while improving antibody performance metrics. As these technologies continue to evolve, they promise even greater advances in specificity, sensitivity, and reproducibility for challenging targets like WD repeat proteins.

What emerging technologies will transform bun107 antibody applications in single-cell analyses?

Emerging technologies are poised to revolutionize bun107 antibody applications in single-cell analyses through several groundbreaking approaches:

Spatial proteomics integration: Advanced multiplexed antibody-based technologies like CODEX (CO-Detection by indEXing) and 4i (iterative indirect immunofluorescence imaging) now enable simultaneous visualization of bun107 alongside dozens to hundreds of other proteins within the same cell. These approaches reveal spatial relationships between bun107 and other factors with unprecedented detail, providing insights into functional protein networks in different cellular states.

Mass cytometry advancements: New generations of CyTOF (Cytometry by Time-Of-Flight) technologies utilize metal-labeled antibodies against bun107 and other targets for highly multiplexed single-cell analysis. Recent innovations include imaging mass cytometry (IMC) and multiplexed ion beam imaging (MIBI), which maintain spatial information while quantifying over 40 proteins simultaneously at subcellular resolution.

Nanobody and aptamer alternatives: The development of nanobodies (single-domain antibody fragments) and aptamers (nucleic acid-based binding molecules) against bun107 addresses limitations of traditional antibodies. These smaller probes improve tissue penetration, enable super-resolution applications with reduced linkage error, and can be easily modified for multiplexed detection schemes.

Single-cell proteogenomic correlation: Emerging platforms now combine antibody-based protein detection with simultaneous RNA sequencing in the same cell. For bun107 research, these approaches correlate protein expression, modification state, and localization with transcriptional profiles, revealing regulatory relationships at unprecedented resolution.

Live-cell antibody applications: Membrane-permeable antibody fragments and intrabodies against bun107 enable real-time tracking of this protein in living cells. These tools, when combined with advanced light-sheet microscopy or lattice light-sheet microscopy, reveal dynamic behaviors and interactions impossible to observe in fixed samples.

These technological frontiers promise to transform our understanding of bun107's roles in cellular processes by providing multidimensional data at single-cell and subcellular resolution, enabling systems biology approaches to WD repeat protein function.

How will interdisciplinary approaches enhance the utility of bun107 antibodies in comparative evolutionary studies?

Interdisciplinary approaches are significantly enhancing the utility of bun107 antibodies in comparative evolutionary studies through several innovative strategies:

Computational phylogenetics integration: Advanced algorithms now analyze WD repeat protein evolution across species, identifying conserved and divergent epitopes. This computational approach guides the development of bun107 antibodies that either: (1) recognize conserved epitopes for cross-species applications, or (2) target species-specific regions for selective detection. These targeted antibodies enable precise tracking of evolutionary changes in protein structure and function.

Structural biology synergy: Cryo-electron microscopy and X-ray crystallography data of WD repeat proteins across species are being integrated with epitope mapping of bun107 antibodies. This approach reveals how structural conservation relates to functional conservation, providing insights into evolutionary constraints on WD repeat proteins. Researchers can select antibodies that recognize structurally conserved or divergent regions based on specific evolutionary questions.

Single-cell evolutionary proteomics: Combining single-cell proteomics with bun107 antibodies allows researchers to examine protein expression variation within and between species. This approach reveals how natural selection acts on protein expression levels and localization patterns, providing insights into the evolutionary dynamics of WD repeat proteins across taxonomic groups.

Ancient protein reconstruction: Using ancestral sequence reconstruction algorithms, researchers can synthesize predicted ancestral versions of bun107 from evolutionary ancestors of modern yeasts. Antibodies developed against these reconstructed proteins enable direct testing of hypotheses about protein function evolution through complementation studies in modern yeasts.

Environmental adaptation studies: Antibodies against bun107 from closely related yeast species adapted to different ecological niches help reveal how WD repeat protein function evolves during environmental adaptation. This approach connects molecular evolution to ecological specialization, providing insights into adaptive evolution at the protein level.

These interdisciplinary approaches transform bun107 antibodies from simple detection tools into sophisticated probes for addressing fundamental questions about protein evolution, connecting molecular changes to functional divergence across evolutionary timescales.

What methodological advances are needed to improve reproducibility in bun107 antibody research?

Several critical methodological advances are needed to address the reproducibility challenges in bun107 antibody research:

Standardized validation reporting: The field urgently needs comprehensive validation reporting standards specifically for antibodies against WD repeat proteins like bun107. This framework should require documentation of all validation approaches employed (genetic, orthogonal, independent epitope), raw validation data, specific experimental conditions, and quantitative performance metrics. Implementation of a standardized "validation passport" that accompanies each antibody would enable researchers to evaluate validation rigor objectively.

Digital authentication systems: Blockchain-based or similar digital authentication systems that track antibody provenance, validation history, and application-specific performance metrics would significantly improve reproducibility. For bun107 research, this would create an immutable record of validation evidence and experimental outcomes accessible to all researchers using a particular antibody.

Recombinant antibody prioritization: Transitioning from traditional hybridoma-derived antibodies to recombinant antibodies with defined sequences for bun107 would eliminate batch-to-batch variation. Recombinant antibodies can be produced with exact sequence fidelity indefinitely, ensuring consistent performance across studies and laboratories.

Automated validation platforms: Development of automated, high-throughput validation platforms specifically optimized for WD repeat proteins would standardize validation processes. These systems would apply multiple validation approaches simultaneously under controlled conditions, generating comprehensive validation profiles that can be directly compared between different bun107 antibodies.

Epitope mapping requirements: Mandatory detailed epitope mapping for all bun107 antibodies would improve reproducibility by clarifying exactly which region of the protein is being detected. For WD repeat proteins, understanding whether an antibody targets a conserved repeat or a unique region is essential for interpreting results across experimental conditions.

Interlaboratory validation networks: Establishing networks of laboratories that systematically validate the same bun107 antibody across different experimental systems, techniques, and applications would provide robust evidence of reliability and highlight application-specific limitations.

Implementation of these methodological advances would transform the reproducibility landscape in bun107 antibody research, building a more solid foundation for scientific progress in understanding WD repeat protein biology.